Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Jun Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1330-9616; OpenAlex author ID A5100450248. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 9

  1. High-density lipoprotein-based nanoplatform reprograms tumor microenvironment and enhances chemotherapy against pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.biomaterials.2025.123147↗
  2. Synthetically Lethal Biomimetic Nutri-hijacker Hitchhikes and Reprograms KRAS Mutation-Driven Metabolic Addictions for Pancreatic Ductal Adenocarcinoma Treatme… Last author DOI 10.1021/acsnano.3c04069↗
  3. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center… Co-author DOI 10.2147/ott.s427942↗
  4. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661↗
  5. Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.898119↗
  6. The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.978921↗
  7. Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2020.119907↗
  8. Tailored Chemodynamic Nanomedicine Improves Pancreatic Cancer Treatment via Controllable Damaging Neoplastic Cells and Reprogramming Tumor Microenvironment. Last author DOI 10.1021/acs.nanolett.0c02622↗
  9. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer. Last author DOI 10.1002/smll.201900631↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yukun Huang · 5 shared papers, 2019–2025 · strength 0.69
  2. Yu Chen · 3 shared papers, 2020–2023 · strength 0.34
  3. Jing Xie · 1 shared paper, 2025 · strength 0.27
  4. Linxi Zhu · 2 shared papers, 2022 · strength 0.25
  5. Changchang Lu · 2 shared papers, 2022 · strength 0.25
  6. Lei Wang · 2 shared papers, 2022 · strength 0.25
  7. Yudong Qiu · 2 shared papers, 2022 · strength 0.25
  8. Xin Qiu · 2 shared papers, 2022 · strength 0.25
  9. Qi Li · 2 shared papers, 2022 · strength 0.25
  10. Juan Du · 2 shared papers, 2022 · strength 0.25
  11. Baorui Liu · 2 shared papers, 2022 · strength 0.25
  12. Qiyong Li · 1 shared paper, 2023 · strength 0.20
  13. Min Xiao · 1 shared paper, 2023 · strength 0.20
  14. Zhitao Chen · 1 shared paper, 2023 · strength 0.20
  15. Sui-Cai Mi · 1 shared paper, 2022 · strength 0.19
  16. Hao Xin Lu · 1 shared paper, 2022 · strength 0.19
  17. Chen Liang · 2 shared papers, 2019–2020 · strength 0.18
  18. Jingxian Feng · 2 shared papers, 2019–2020 · strength 0.18
  19. Ju Dong Yang · 1 shared paper, 2022 · strength 0.12
  20. Hao Cheng · 1 shared paper, 2022 · strength 0.12
  21. Qian Zhang · 1 shared paper, 2019 · strength 0.08
  22. Yuanyuan Pei · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.